Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion type Assertion NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_head.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion description "[The results show that combination immunotherapy consisting of vaccination with a synthetic peptide corresponding to an immunodominant CTL epitope derived from tyrosinase-related protein-2 administered with CpG-ODN adjuvant and followed by systemic injection of anti-CTLA-4 antibodies increased the survival of mice against the poorly immunogenic B16 melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_provenance.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion evidence source_evidence_literature NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_provenance.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion SIO_000772 12810660 NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_provenance.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion wasDerivedFrom befree-20150227 NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_provenance.
- NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_assertion wasGeneratedBy ECO_0000203 NP335081.RAsZ8AqbjRW4QaMzNr28EzI-HjxiGK1JagL6rw-2_-YFw130_provenance.